56106-05-9

Basic information

• Product Name: AKOS BBS-00007770
• Synonyms: AKOS BBS-00007770;AURORA 2268;BUTTPARK 41\07-62;ASISCHEM D13225;4'-METHOXYSUCCINANILIC ACID;4-[(4-methoxyphenyl)amino]-4-oxobutanoic acid
• CAS NO: 56106-05-9
• Molecular Formula: C₁₁H₁₃NO₄
• Molecular Weight: 223.23
• Mol File: 56106-05-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 491.9°Cat760mmHg
• Flash Point: 251.3°C
• Appearance: /
• Density: 1.281g/cm³
• Vapor Pressure: 1.71E-10mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: AKOS BBS-00007770(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BBS-00007770(56106-05-9)
• EPA Substance Registry System: AKOS BBS-00007770(56106-05-9)

Safety Data

• Hazardous Substances Data: 56106-05-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H13NO4/c1-16-9-4-2-8(3-5-9)12-10(13)6-7-11(14)15/h2-5H,6-7H2,1H3,(H,12,13)(H,14,15)

Upstream product

• 2314-80-9 2-(4-methoxyphenyl)succinimide 
• 108-31-6 maleic anhydride 
• 104-94-9 4-methoxy-aniline 
• 108-30-5 succinic acid anhydride 

Downstream Products

• 2314-80-9 2-(4-methoxyphenyl)succinimide 
• 110-15-6 succinic acid 
• 104-94-9 4-methoxy-aniline 
• 1081-17-0 N-(4-methoxyphenyl)maleimide 
• 356550-44-2 C₁₃H₁₇NO₄ 
• 105461-04-9 4-Hydroxy-N-(4-methoxy-phenyl)-butyramide 
• 1332878-15-5 N-(2-methoxy-4-methylphenyl)-N'-(4-methoxyphenyl)oxalamide 
• 92847-23-9 N-(3-bromo-4-methoxy)phenylsuccinimide 
• 356539-11-2 4-[(4-methoxyphenyl)amino]butan-1-ol 

Relevant articles and documents

Design, synthesis and anticancer activity of naphthoquinone derivatives

Basis on molecular docking and pharmacophore analysis of naphthoquinone moiety, a total of 23 compounds were designed and synthesised. With the help of reverse targets searching, anti-cancer activity was preliminarily evaluated, most of them are effective against some tumour cells, especially compound 12: 1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl-4-oxo-4-((4-phenoxyphenyl)amino) butanoate whose IC50 against SGC-7901 was 4.1 ± 2.6 μM. Meanwhile the anticancer mechanism of compound 12 had been investigated by AnnexinV/PI staining, immunofluorescence, Western blot assay and molecular docking. The results indicated that this compound might induce cell apoptosis and cell autophagy through regulating the PI3K signal pathway.

A facile and green synthesis of N-substituted imides

Anhydrides 1, 6 and 10 have been reacted, independently, with aromatic primary amines 2 in solid phase by simple physical grinding of reactants with p-toluenesulphonicacid as a catalyst to yield corresponding open chain derivatives, monoacid monoamides3,7 and 11 respectively. The latter have each been transformed into the corresponding cyclic derivatives, i.e. imides 5, 9 and 13 respectively in solid phase by simple physical grinding of each with K 2CO3, alkylating agent and tetrabutylammoniumbromide as a catalyst with short reaction times. These cyclic imides can also be obtained by physical grinding of each of 3, 7 and 11 with dicyclohexylcarbodimide as a dehydrating agent in solid phase.

Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads

Glycogen phosphorylase (GP) is a valid anti-diabetic target. Accordingly, we applied a drug discovery workflow to unveil novel inhibitory GP leads via combining pharmacophore modeling, QSAR analysis and in silico screening, followed by synthetic exploration of active hits. Virtual screening identified six low micromolar inhibitory leads from the National Cancer Institute (NCI) list of compounds. The most potent hits exhibited anti-GP IC50 values of 3.2 and 4.1 μM. Synthetic exploration of hit 59 (IC50 = 4.1 μM) yielded 25 lead inhibitors with the best illustrating IC50 of 3.0 μM. Interestingly, we prepared several novel mixed oxalyl amide anti-GP leads employing new chemical reaction involving succinic acid-based adducts.